Clearside Biomedical Announces Multiple Presentations to be Given at the American Academy of Ophthalmology (AAO) 2019 Annual ...
03 Octubre 2019 - 6:05AM
Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical
company dedicated to developing and delivering treatments that
restore and preserve vision for people with serious back of the eye
diseases, announced today that multiple oral presentations on
Clearside’s pipeline and proprietary SCS Microinjector™ targeting
the suprachoroidal space will be given at the upcoming American
Academy of Ophthalmology (AAO) 2019 Annual Meeting taking place
October 12-15, 2019 in San Francisco, California.
Presentation Details:
Title: |
Suprachoroidal
CLS-TA and IOP: Results from the Phase 3 PEACHTREE Clinical
Trial |
Author: |
Steven Yeh, M.D., Associate Professor, Emory Eye Center |
Date/Time: |
Sunday, October 13th / 3:15 p.m.; also available as an
ePoster |
Poster #: |
PO522 |
|
|
Title: |
Suprachoroidal Delivery for Ocular Gene Therapy: Nonclinical
Experiments Evaluating Nonviral DNA Nanoparticles |
Author: |
Christine N. Kay, M.D., Vitreo Retinal Associates; Affiliate
Assistant Professor in the Department of Ophthalmology, University
of South Florida |
Date/Time: |
Sunday, October 13th / 5:00 p.m.; also available as an
ePoster |
Poster #: |
PO395 |
|
|
Title: |
A Subgroup Analysis of Subjects Diagnosed With Anterior Uveitis
From the Phase 3 PEACHTREE Clinical Trial |
Author: |
Ashleigh L. Levison, M.D., Colorado Retina Associates |
Date/Time: |
Monday, October 14th / 8:30 a.m. |
Paper #: |
PA031 |
|
|
Title: |
Disorganization of the Retinal Inner Layers as a Biomarker:
Results of the TYBEE Phase 2 in DME |
Author: |
Michael S. Ip, M.D., Doheny Eye Institute, David Geffen School
of Medicine at University of California Los Angeles, CA |
Date/Time: |
ePoster |
Poster #: |
PO485 |
About Clearside Biomedical
Clearside Biomedical, Inc. is a
biopharmaceutical company dedicated to developing and delivering
treatments that restore and preserve vision for people with serious
back of the eye diseases. Clearside’s proprietary SCS
Microinjector™ targeting the suprachoroidal space (SCS) offers
unique access to the macula, retina and choroid where
sight-threatening disease often occurs. The Company’s SCS injection
platform is an inherently flexible, in-office, non-surgical
procedure, intended to provide targeted delivery to the site of
disease and to work with both established and new formulations of
medications, as well as future therapeutic innovations such as gene
therapy. For more information, please visit
www.clearsidebio.com.
Cautionary Note Regarding
Forward-Looking Statements
Any statements contained in this press release
that do not describe historical facts may constitute
forward-looking statements as that term is defined in the Private
Securities Litigation Reform Act of 1995. These statements may be
identified by words such as “believe”, “expect”, “may”, “plan”,
“potential”, “will”, and similar expressions, and are based on
Clearside’s current beliefs and expectations. These forward-looking
statements include statements regarding the potential to bring
XIPERE to market for uveitis patients, opportunities for expanding
Clearside’s internal pipeline, and the potential benefits of XIPERE
and the SCS injection platform. These statements involve risks and
uncertainties that could cause actual results to differ materially
from those reflected in such statements. Risks and uncertainties
that may cause actual results to differ materially include
uncertainties inherent in the conduct of clinical trials,
Clearside’s reliance on third parties over which it may not always
have full control, and other risks and uncertainties that are
described in Clearside’s Annual Report on Form 10-K for the year
ended December 31, 2018, filed with the U.S. Securities and
Exchange Commission (“SEC”) on March 15, 2019, Clearside’s
Quarterly Report on Form 10-Q for the quarter ended June 30, 2019,
filed with the SEC on August 8, 2019, and Clearside’s other
Periodic Reports filed with the SEC. Any forward-looking statements
speak only as of the date of this press release and are based on
information available to Clearside as of the date of this release,
and Clearside assumes no obligation to, and does not intend to,
update any forward-looking statements, whether as a result of new
information, future events or otherwise.
Investor and Media Contacts: Jenny Kobin Remy
Bernarda ir@clearsidebio.com(678) 430-8206
Source: Clearside Biomedical, Inc.
Clearside Biomedical (NASDAQ:CLSD)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Clearside Biomedical (NASDAQ:CLSD)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024